Cochrane · systematic review · CD006539
Neuroprotection for treatment of glaucoma in adults
Sena, DF, Lindsley, K · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
8
current version
GRADE rated
3
No studies
5
Included studies
NR
No studies 5 · 62.5%Ungraded 0 · 0%Very low 3 · 37.5%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Neuroprotection compared with control for glaucoma
Population: adults with open angle glaucoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes* Neuroprotection vs control | no estimate extracted | NR | No studies |
Visual field: the proportion of participants with progression of visual field loss at 4 years' Neuroprotection vs control | RR 0.35 [0.14, 0.86] | 1 study · 101 participants | Very low Downgraded: risk of bias |
Visual acuity: the proportion of participants with loss of visual acuity at 4 years' Neuroprotection vs control | no estimate extracted | NR | No studies |
Intraocular pressure: mean IOP at 4 years' Neuroprotection vs control | MD 0.2 | 1 study · 91 participants | Very low Downgraded: risk of bias |
Vertical cup‐disc ratio: the proportion of participants with asymmetrical vertical cup‐disc ratio greater than 0.3 at 4 years' Neuroprotection vs control | no estimate extracted | NR | No studies |
Adverse effects: ocular allergy to the study medication requiring discontinuation up to 4 years' Neuroprotection vs control | RR 5.32 [1.64, 17.26] | 1 study · 178 participants | Very low Downgraded: risk of bias |
Quality of life measures Neuroprotection vs control | no estimate extracted | NR | No studies |
Economic data Neuroprotection vs control | no estimate extracted | NR | No studies |